Skip to content
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Illumina, Inc. ILMN

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.3B
▼ 0.7% YoY
$850.0M
$931.0M
▲ 31.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis, and its products and services serve customers in research and clinical settings. Its product sales primarily consist of sequencing- and array-based instruments and consumables, including reagents, flow cells and library preparation, and it also performs various services for its customers. As of December 28, 2025, its global workforce was comprised of approximately 8,600 full time employees, 50 part time employees, and 1,430 contingent workers. Shipments to customers outside the United States totaled $2,100 million, or 48% of total consolidated revenue, in 2025. The company has one reportable segment, Core Illumina, as of December 28, 2025, following the June 24, 2024 spin-off of GRAIL into a separate, independent publicly traded company. Illumina, Inc. was incorporated in California in April 1998 and reincorporated in Delaware in July 2000.

Written from the business description in ILLUMINA, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.

Growth

USD 4.3B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 4.3 · Net income 0.8
2B4B-2B-4B
2008201120142017202020232025
Compound annual growth
−1.8%
+6.0%
+6.9%
+11.0%
+6.3%
+13.6%
+4.1%
+5.8%
+13.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

20 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 18.6% · Net 19.6%
10%20%-50%
200820162025
ROE
FY2025 · ROE 33.4%
10%20%30%-20%-40%
200820162025
Three returns, three denominators.

Each USD of equity produced 33 cents of profit this year.

Cash & shareholders

USD 698.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 931.0
400M800M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 698.0
250.0M500.0M
2008201120142017202020232025

USD 698.0M in buybacks — 82% of the year's profit went back to shareholders.

Total assetsUSD 6.6B
EquityUSD 2.7B
CashUSD 1.4B
Current ratio2.08×

Equity funds 41% of total assets.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ILMN, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B4.34.44.54.64.53.23.53.32.82.42.21.91.41.11.10.90.70.6
Operating income $B0.8−0.8−1.1−4.2−0.10.61.00.90.60.60.60.50.10.20.20.20.10.1
EBITDA $B1.1−0.5−0.6−3.80.10.81.21.10.80.70.70.60.20.20.30.20.20.1
Income tax $B0.20.00.00.10.10.20.10.10.40.10.10.10.00.10.00.10.00.0
Net income $B0.8−1.2−1.2−4.40.80.71.00.80.70.50.50.40.10.20.10.10.10.0
Free cash flow $B0.90.70.30.10.30.90.80.80.60.50.60.40.30.20.30.20.10.0
EPS, diluted $5.45−7.69−7.34−28.005.044.456.745.564.923.073.102.370.901.130.620.870.530.30
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %33.4−30.1−18.8−50.89.914.123.925.429.422.927.923.68.812.67.612.18.74.9
Shares out B0.150.160.160.160.160.150.150.150.150.150.150.140.130.120.120.13◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJanuary 3
Data on record since2008

Share this section

Download image